Companies Cryptocurrencies
Provention Bio Inc
Provention Bio Inc
Exchange: NasdaqGS
IPO Date: 24/07/2018
CEO: Mr. Ashleigh Palmer
Biotechnology Healthcare đź”—
  • PRVB
  • 6.6
  • 418273024
    market cap
  • -0.1500001
If you bought

shares of Provention Bio Inc (PRVB) on
You would have made
Old Price $12 Current Price $12

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. The company is headquartered in Oldwick, New Jersey and currently employs 13 full-time employees. The firm aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D.

Address: PO Box 666 Oldwick NEW JERSEY 08858

Stay updated.